High-Sensitivity Cardiac Troponin Publications during the COVID-19 Pandemic (2020–2022)

The first publications detailing the clinical utility of high-sensitivity cardiac troponin (hs-cTn) in patients with possible acute coronary syndrome (ACS) are traceable to 2009 [...].

The first publications detailing the clinical utility of high-sensitivity cardiac troponin (hs-cTn) in patients with possible acute coronary syndrome (ACS) are traceable to 2009 [1][2][3]. In early 2020, I wrote an editorial where I concluded that, "before we obtain 20/20 vision for hs-cTn testing in and outside the ACS setting additional publications and data from all assays will be needed" [3]. This publication coincided with the commencement of the COVID-19 pandemic and, surprisingly, the acceleration of publications with hs-cTn in and outside the ACS setting, with the majority of manufacturers and their hs-cTn assays ( Figure 1). The COVID-19 pandemic has not only increased the number of scientific articles, but also the impact factor for journals, which is a testament to the scientific community's response to the pandemic [4]. Regarding cardiac biomarkers and laboratory tests, early in the course of the pandemic, data was emerging regarding possible cardiac complications   The COVID-19 pandemic has not only increased the number of scientific articles, but also the impact factor for journals, which is a testament to the scientific community's response to the pandemic [4]. Regarding cardiac biomarkers and laboratory tests, early in the course of the pandemic, data was emerging regarding possible cardiac complications and COVID-19 [5,6]. In particular, some younger patients that were not hospitalized for COVID-19 may develop myocardial injury during their recovery [6]. The role of an objective biomarker 2 of 4 here, such as hs-cTn, is extremely valuable; albeit not all hs-cTn elevations following COVID-19 infection or immunization against the virus reflect ongoing, acute injury [7]. Macrocomplexes may be a possible culprit for some of these elevations in some patients in this setting, and outside of COVID-19, macrocomplexes and other new interferences as well as different combinations of known (pre-analytical) variables may result in discordant hs-cTn levels as highlighted in articles published in the past couple of years [7][8][9][10][11][12].
The impact of interferences resulting in falsely elevated hs-cTn concentrations is not trivial, with reports for one manufacturer's assay yielding not only a higher prevalence of myocardial injury due to the presence of an interference but also a higher rate of difficultto-reproduce results (i.e., high imprecision) [10]. The latter finding of poor reproducibly is terribly important as many guidelines have recommended pathways that incorporate a change in hs-cTn concentrations to either rule-out or rule-in myocardial infarction (MI) in patients with symptoms suggestive of ACS [13,14]. To that end, the clinical laboratory needs to provide a highly precise and a robust hs-cTn assay or pathway, to prevent patient misclassification due to suboptimal analytical variation or the presence of interferences impacting measurements. Even here, not all pathways will achieve the same level of diagnostic performance [14,15]. Specifically, in an undifferentiated emergency department (ED) patient population being evaluated with hs-cTn, none of the pathways/algorithms (e.g., the European Society of Cardiology, High-STEACS, COMPASS-MI) which use hs-cTn alone achieved a sensitivity ≥99% for MI or death at thirty days following the ED presentation [15]. However, algorithms incorporating additional laboratory tests (i.e., troponin plus other laboratory tests), can achieve the 99% sensitivity benchmark [16], with the application of these laboratory-based algorithms yielding higher sensitivity estimates for thirty day MI or death as compared to hs-cTn alone as evident in very large ED population datasets [17,18].
Outside of COVID-19 and the ED setting, publications have also identified unique aspects pertinent for hs-cTn. For example, in patients undergoing cardiac surgery preoperative and post-operative hs-cTn measurements may provide clinical utility [19,20]. Importantly, levels of hs-cTn greater than 200 times the upper reference limit within one day after cardiac surgery are prognostic, which is a much higher level than what is stated in the universal definition of myocardial infarction [20,21]. In fact, the utility of hs-cTn extends beyond these settings with possible important roles in cancer therapy related cardiotoxicity, in heart failure and other supply-demand mismatch situations [22][23][24][25].
When my 2020 editorial was available online (25 January 2020); "The WHO Regional Director for Europe issued a public statement outlining the importance of being ready at the local and national levels for detecting cases, testing samples and clinical management." https://www.who.int/emergencies/diseases/novel-coronavirus-2019/interactive-timeline#! (accessed on 11 December 2022). The exponential growth of SARS-CoV-2 infection did not equate to the exponential growth of publications related to hs-cTn (see Figure 1). However, the increased number of publications related to hs-cTn during this time has indeed diminished the knowledge gap as outlined in the 2020 editorial and even opened the door to new approaches and pathways for this important laboratory test.
Funding: This research received no external funding.
Conflicts of Interest: P.A. Kavsak has received grants/reagents/consultant/advisor/honoraria from Abbott Laboratories, Abbott Point of Care, Beckman Coulter, Ortho Clinical Diagnostics, Randox Laboratories, Roche Diagnostics, Quidel, Siemens Healthcare Diagnostics and Thermo Fisher Scientific. McMaster University has filed patents with P.A. Kavsak listed as an inventor in the acute cardiovascular biomarker field. In particular, a patent has been granted by the EPO related to work referenced in this paper: "Method of determining risk of an adverse cardiac event".